natgillin/translations-raw huggingface dataset:
De farmakologiske egenskaber af de lægemidler, der er brugt tidligere, bør tages med i overvejelserne for længden af den behandlingsfrie periode.
The treatment- free period should take into account the pharmacological properties of the medicinal products used previously.
De farmakologiske egenskaber af de præparater, der er brugt tidligere, bør tages med i overvejelserne for længden af den behandlingsfrie periode.
The treatment- free period should take into account the pharmacological properties of the products used previously.
De farmakologiske egenskaber af de præparater, der er brugt tidligere, skal tages med i overvejelserne for længden af den behandlingsfrie periode.
The treatment-free period should take into account the pharmacological properties of the products used previously.
De farmakologiske egenskaber af de veterinære lægemidler, der er brugt tidligere, bør tages med i overvejelserne for længden af den behandlingsfrie periode.
The treatment-free period should take into account the pharmacological properties of the medicinal products used previously.
De farmakologiske virkninger af beta2-adrenoceptoragonister kan som minimum delvist tilskrives stimulering af intracellulær adenylcyclase, det enzym, som katalyserer omdannelsen af adenosintrifosfat (ATP) til cyklisk-3’, 5’-adenosinmonofosfat (cyklisk monofosfat).
The pharmacological effects of beta2-adrenoceptor agonists are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyses the conversion of adenosine triphosphate (ATP) to cyclic-3’, 5’-adenosine monophosphate (cyclic monophosphate).
De farmakologiske virkninger af beta2-adrenoceptoragonister, inklusive indacaterol, kan som minimum delvist tilskrives stimulering af intracellulær adenylcyclase, det enzym, som katalyserer omdannelsen af adenosintrifosfat (ATP) til cyklisk-3’, 5’-adenosinmonofosfat (cyklisk AMP).
The pharmacological effects of beta2-adrenoceptor agonists, including indacaterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyses the conversion of adenosine triphosphate (ATP) to cyclic-3’, 5’-adenosine monophosphate (cyclic AMP).
De farmakologiske virkninger af beta2-agonister, herunder vilanterol, kan i det mindste delvist tilskrives stimulering af intracellulær adenylatcyklase, som er det enzym, der katalyserer omdannelsen af adenosintrifosfat (ATP) til cyklisk 3',5'-adenosinmonofosfat (cyklisk AMP).
The pharmacologic effects of beta2-adrenergic agonists, including vilanterol, are at least in part attributable to stimulation of intracellular adenylate cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’,5’-adenosine monophosphate (cyclic AMP).
De farmakologiske virkninger ved behandling med β2-agonister, såsom tremor, palpitationer og hovedpine, er blevet rapporteret med en tendens til at være forbigående og aftagende ved regelmæssig behandling.
The pharmacological effects of β2 agonist treatment, such as tremor, palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy.
De faste partikler indeholder medicin – de må ikke tygges eller knuses
The solid pieces contain the medicine – do not chew or crush them.
De fem hovedundersøgelser af Sprycel taget to gange dagligt omfattede 515 patienter, der alle forinden havde fået behandling med imatinib, som enten havde været virkningsløs, eller hvor patienterne var blevet resistente over for behandlingen.
The five main studies of Sprycel, taken twice a day, involved 515 patients, all of whom had received prior treatment with imatinib and had either failed to respond or become resistant to it.
De fik 50 mg/kg saquinavir 2 gange daglig (højst 1.000 mg 2 gange daglig) boostet med ritonavir 3 mg/kg for patienter med legemsvægt i intervallet 5 kg til < 15 kg og 2,5 mg/kg for patienter med legemsvægt i intervallet 15 kg til 40 kg (højst 100 mg 2 gange daglig).
<6 years and received 50 mg/kg saquinavir bid (not to exceed 1000 mg bid) boosted with ritonavir at 3 mg/kg for patients with body weight ranging from 5 to <15 kg or 2.5 mg/kg for patients with body weight ranging from 15 to 40 kg (not to exceed 100 mg bid).
De fik 50 mg/kg saquinavir to gange daglig (højst 1.000 mg to gange daglig) boostet med ritonavir 3 mg/kg for patienter med legemsvægt i intervallet 5 kg til < 15 kg og 2,5 mg/kg for patienter med legemsvægt i intervallet 15 kg til 40 kg (højst 100 mg to gange daglig).
<6 years and received 50 mg/kg saquinavir bid (not to exceed 1000 mg bid) boosted with ritonavir at 3 mg/kg for patients with body weight ranging from 5 to <15 kg or 2.5 mg/kg for patients with body weight ranging from 15 to 40 kg (not to exceed 100 mg bid).
De fik alle 75 mg 13C-urea, med undtagelse af 204 børn under 11 år, som fik 45 mg.
All received 75 mg of 13C-urea, except 204 children under the age of 11 who received 45 mg.
De filmomhulde tabletten zijn roze, rond en licht bol aan één zijde.
The film-coated tablets are pink, round and slightly convex.
De filmovertrukne 5 mg tabletter er hvide, ovale, bikonvekse filmovertrukne tabletter med en størrelse på 8 mm x 4,5 mm og præget med “M5” på den ene side.
The 5 mg film-coated tablets are white, oval shaped, biconvex film-coated tablets, 8 mm x 4.5 mm in size, with the marking “M5” engraved on one side.
De filmovertrukne Invirasetabletter skal synkes hele og tages samtidig med ritonavir, samtidig med eller efter fødeindtagelse (se pkt.
Invirase film-coated tablets should be swallowed whole and taken at the same time as ritonavir with or after food (see section 5.2).
De filmovertrukne tabletter består af en kernetablet, omgivet af filmovertræk for at undgå, at sundhedspersonalet udsættes for det aktive stof.
The film-coated tablets consist of a core tablet, surrounded by a film coating to prevent exposure of health care professionals to the active substance.
De filmovertrukne tabletter er aflange og hvide til råhvide mærket L2/IT.
The film-coated tablets are of oblong shape and white to off-white in colour, engraved L2/IT.
De filmovertrukne tabletter er hvide til offwhite, aflange, bikonvekse, 14,6 mm lange og 6,7 mm brede, præget med ”300” på den ene side og jævne på den anden side.
The film-coated tablets are white to off white, oblong shaped, biconvex, 14.6 mm in length and 6.7 mm in width, debossed with ‘300’ on one side and plain on other side.
De filmovertrukne tabletter er hvide, runde, bikonvekse tabletter leveret i polyamid/aluminium/PVC - aluminium blisterpakninger.
The film-coated tablets are white, round biconvex tablets supplied in Polyamide/Al/PVC - Aluminum foil blister.
De filmovertrukne tabletter er hvide, runde, bikonvekse tabletter og leveres i polyamid/aluminium/PVC - aluminium blisterpakninger.
The film-coated tablets are white, round biconvex tablets supplied in Polyamide/Al/PVC - Aluminum foil blister.
De filmovertrukne tabletter er lyse ferskenfarvede, aflange, bikonvekse, 11,4 mm lange og 5,3 mm brede, præget med ”150” på den ene side og jævne på den anden side.
The film-coated tablets are light peach colored, oblong shaped, biconvex, 11.4 mm in length and 5.3 mm in width, debossed with ‘150’ on one side and plain on other side.
De filmovertrukne tabletter er lyserøde til pink, filmovertrukne kapselformede tabletter.
The film-coated tablets are light pink to pink, film coated, capsule shaped tablets.
De filmovertrukne tabletter er lyserøde, runde og bikonvekse.
The film-coated tablets are pink, round and biconvex.
De filmovertrukne tabletter er modificeret kapselformede, lysegule til lysebrune og præget med ‘FX75’ på den ene side.
The film-coated tablets are modified capsule-shaped, pale yellow to light-tan and debossed with ‘FX75’ on one side.
De filmovertrukne tabletter er modificeret kapselformede, pink-orange til ferskenfarvet og præget med ‘FX100’ på den ene side.
The film-coated tablets are modified capsule-shaped, pink-orange to peach and debossed with ‘FX100’ on one side.
De filmovertrukne tabletter er ovale beige tabletter med “770” præget på den ene side og uden prægning på den anden side.
The film-coated tablets are beige, oval, debossed with “770” on one side and plain on the other.
De filmovertrukne tabletter er ovale bikonvekse, lys ferskenfarvede, 11,5 mm x 5,4 mm præget med “C” på den ene side og “150”på den anden.
The film-coated tablets are oval biconvex light peach, 11.5 mm x 5.4 mm with inscription “C” on one side and “150”on the other side.
De filmovertrukne tabletter er ovale bikonvekse, lys ferskenfarvede, 16,0 mm x 8,5 mm præget med “C” på den ene side og “500”på den anden.
The film-coated tablets are oval biconvex light peach, 16.0 mm x 8.5 mm with inscription “C” on one side and “500”on the other side.
De filmovertrukne tabletter indeholder: Mikrokrystallinsk cellulose Povidon K 25
Film-coated tablet contents: Microcrystalline cellulose Povidone K 25 Crospovidone
De filmovertrukne tabletter kan indtages med eller uden mad.
The film-coated tablets can be taken with or without food.
De findes i blistermultipakninger med 120, 120x1 (4 æsker med 30 eller 30x1) eller 360 (12 æsker med 30) filmovertrukne tabletter og i plastflasker (der indeholder et tørremiddel, som ikke må spises) med 120 filmovertrukne tabletter og en multipakning, der indeholder 360 (3 flasker med 120) filmovertrukne tabletter.
They are available in blister multipacks of 120, 120x1 (4 cartons of 30 or 30x1) or 360 (12 cartons of 30) film-coated tablets and in plastic bottles (containing a desiccant, which should not be eaten) of 120 film- coated tablets and a multipack containing 360 (3 bottles of 120) film-coated tablets.
De findes i blisterpakninger på 30 og 60 tabletter og som tabletglaspakninger i pakningsstørrelse på 30, 60, 100 og 200 filmovertrukne tabletter.
It is available in blisters in pack sizes of 30 and 60 tablets and in glass bottles in pack sizes of 30, 60 ,100 and 200 film- coated tablets.
De findes i pakker med 30, 50 og 100 depotkapsler, hårde, i blister og i pakker med 30x1, 50x1 og 100x1 depotkapsler, hårde, i perforeret enkeltdosisblister.
Packs of 30, 50 and 100 prolonged-release capsules are available in blisters and packs of 30×1, 50×1 and 100×1 prolonged-release capsules are available in perforated unit-dose blisters.
De findes i pakker med 30, 50 og 100 depotkapsler, hårde, i blister og i pakker med 30x1, 50x1 og 100x1 depotkapsler, hårde, i perforeret enkeltdosisblister.
Packs of 30, 50 and 100 prolonged-release hard capsules are available in blisters and packs of 30×1, 50×1 and 100×1 prolonged-release capsules are available in perforated unit-dose blisters.
De findes i pakker med 30, 50, 60 og 100 depotkapsler, hårde, i blister og i pakker med 30x1, 50x1, 60x1 og 100x1 depotkapsler, hårde, i perforeret enkeltdosisblister.
Packs of 30, 50, 60 and 100 prolonged-release capsules are available in blisters and packs of 30×1, 50×1, 60×1 and 100×1 prolonged-release capsules are available in perforated unit-dose blisters.
De findes i pakninger med 100 eller 300 kapsler (begge i blisterkort med 10 stk.).
They are available as a carton of 100 or 300 capsules (both in blister packs of 10).
De findes i pakninger med 50 eller 150 tabletter (begge i blisterpakninger a 10 stk.).
They are available as packs of 50 or 150 tablets (both in blister packs of 10).
De fleste
Most tyrosine kinase
De fleste (83,3%) af patienterne havde persisterende eller tilbagevendende Cushings sygdom, og kun få (≤5%) i begge behandlingsgrupper havde gennemgået strålebehandling af hypofysen.
Most (83.3%) patients had persistent or recurrent Cushing’s disease and few (≤5%) in either treatment group had received previous pituitary irradiation.
De fleste (95% af patienterne) havde metastaserende sygdom.
Most (95% of the patients) had metastatic disease.
De fleste af bivirkningerne er milde og forsvinder generelt med tiden.
Most of the side effects are mild and will generally disappear over time.
De fleste af bivirkningerne er milde til moderate og forsvinder generelt nogle få dage eller uger efter behandlingen.
Most of the side effects are mild to moderate and will generally disappear a few days to a few weeks after treatment.
De fleste af bivirkningerne forsvinder ved passende behandling eller ved ophør af brugen af Keytruda.
Most will resolve following appropriate treatment or on stopping Keytruda.
De fleste af bivirkningerne i tabel 3 var af sværhedsgrad 1 i regimer med Viekirax og dasabuvir-holdige regimer.
The majority of adverse reactions presented in Table 3 were of grade 1 severity in Viekirax and dasabuvir- containing regimens.
De fleste af bivirkningerne svinder ved passende behandling eller ved at ophøre med brug af Opdivo.
Most will resolve following appropriate treatment or on stopping Opdivo.
De fleste af de fejlslåede behandlinger i CAP-001 var frårsaget af dårlig tolerance.
Most of the treatment failures in CAP-001 were caused by poor tolerability.
De fleste af de indberettede bivirkninger var af sværhedsgrad 1 eller 2. de hyppigste NCI-CTCAE (National Cancer Institute - Common Terminology Criteria for Adverse Events) grad ≥3 bivirkninger (>2%) trombocytopeni, forhøjede aminotransferase-r, anæmi, neutropeni, træthed, hypokaliæmi, muskuloskeletale smerter og blødning.
The majority of ADRs reported were of Grade 1 or 2 severity. the most common National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade ≥ 3 ADRs (> 2%) were thrombocytopenia, increased transaminases, anaemia, neutropenia, fatigue, hypokalaemia, musculoskeletal pain and haemorrhage.
De fleste af de patienter, der bruger Zyclara, kommer ud for lokal hudpåvirkning (oftest rødme, skor- pedannelse og tør, skællende hud ).
Most patients using Zyclara experience local skin side effects (most commonly redness, scab formation, dryness and shedding of the skin).
De fleste af de rapporterede bivirkninger var forbigående og af mild intensitet.
Most of the adverse reactions reported were transient and of mild intensity.
De fleste af dem er milde og kan afhjælpes.
Most of them are mild in nature and reversible.
De fleste af disse abnorme ekg’er var ikke associeret med bivirkninger.
Most of these ECG abnormalities were not associated with adverse reactions.
De fleste af disse bivirkninger forekom oftere hos patienter med parkinsons sygdom.
Most of these side effects occur more frequently in patients with Parkinson’s disease.
De fleste af disse bivirkninger var lette til moderate.
Most of these adverse reactions were mild to moderate in severity.
De fleste af disse bivirkninger var lette, med alvorlige tilfælde (grad 3) rapporteret i 17 % - 19,5 %.
These effects were mostly mild, with severe (grade 3) cases reported in 17%-19.5%.
De fleste af disse bivirkninger var også meget almindelige hos børn.
Most of these side effects were also very common in children.
De fleste af disse patienter havde tidligere fået antracyklinbehandling, 11 % havde tidligere fået trastuzumab.
Most of these patients had received prior anthracycline therapy and 11% of all patients had received prior trastuzumab.
De fleste af disse reaktioner var af en ikke-alvorlig, let til moderat intensitet.
Most of these reactions were non-serious, mild to moderate in intensity.
De fleste af disse reaktioner var lette til moderate.
Most of the reactions were mild or moderate in severity.
De fleste af disse reaktioner var makulopapulære eller urtikarielle udslæt..
The majority of these reactions were maculopapular or urticarial rashes.
De fleste af disse reaktioner var makulopapuløse eller urtikarielle udslæt.
The majority of these reactions were maculopapular or urticarial rashes.
De fleste af disse reaktioner viste sig inden for 2 dage efter vaccinationen.
Most of these reactions were noted during the 2 days following the vaccine injection
De fleste af patienterne (83,3%) havde persisterende eller tilbagevendende Cushings sygdom og kun få (≤5%) i begge behandlingsgrupper havde tidligere gennemgået strålebehandling af hypofysen.
Most patients (83.3%) had persistent or recurrent Cushing’s disease and few (≤5%) in either treatment group had received previous pituitary irradiation.
De fleste af patienterne havde et langt forløb med CML med ekstensiv forudgående behandling med andre antineoplastiske stoffer, inkl. imatinib, hydroxyurea, interferon, og nogle med mislykket organtransplantation (tabel 9).
The majority of patients had a long history of CML that included extensive prior treatment with other antineoplastic agents, including imatinib, hydroxyurea, interferon, and some had even failed organ transplant (Table 9).
De fleste af patienterne i begge behandlingsgrupper havde ingen øget funktionsnedsættelse i 5 års-perioden.
The majority of patients in both treatment groups had no disability progression over the 5-year period.
De fleste af patienterne med blødningshændelser under behandlingen rapporterede blå mærker (65,3%).
Most of the patients with bleeding events during the treatment reported bruising (65.3%).
De fleste af ændringerne i laboratorieværdierne for de kliniske forsøg med PegIntron/ribavirin var milde eller moderate.
Most of the changes in laboratory values in the PegIntron/ribavirin clinical trial were mild or moderate.
De fleste af ændringerne i laboratorieværdierne for de kliniske forsøg med ribavirin/peginterferon alfa- 2b var milde eller moderate.
Most of the changes in laboratory values in the ribavirin/peginterferon alfa-2b clinical trial were mild or moderate.
De fleste af ændringerne i laboratorieværdierne for de kliniske forsøg med ViraferonPeg/ribavirin var milde eller moderate.
Most of the changes in laboratory values in the ViraferonPeg/ribavirin clinical trial were mild or moderate.
De fleste bivirkninger er af let til moderat grad.
Most side effects are mild to moderate.
De fleste bivirkninger er dog milde, forbigående og forsvinder i løbet af 30 minutter efter indgivelse af Rapiscan.
However, most adverse reactions are mild and transient, resolving within 30 minutes after receiving Rapiscan.
De fleste bivirkninger er lette til moderate.
Most side effects are mild to moderate in severity.
De fleste bivirkninger er milde eller moderate, men nogle kan være alvorlige og kræve behandling.
Most side effects are mild to moderate but some may be serious and need treatment.
De fleste bivirkninger er milde eller moderate, og den alvorligste er lungebetændelse.
The majority of side effects are mild or moderate in severity, and the most serious is pneumonia.
De fleste bivirkninger er milde og forbigående.
The majority of adverse reactions are mild and transient.
De fleste bivirkninger forårsages af afslapning af de glatte muskelceller i vaskulaturen eller mave- tarm-kanalen.
Most of the adverse reactions are caused by relaxation of smooth muscle cells in vasculature or the gastrointestinal tract.
De fleste bivirkninger med relation til fotodynamisk behandling er lokale virkninger, der ses som følge af, at Foscan aktiveres af laseren.
Most of the side effects related with photodynamic therapy are local effects seen as consequence of triggering the Foscan with the laser.
De fleste bivirkninger opstod i løbet af de første 48 behandlingsuger.
Most ADRs occurred in the first 48 weeks of treatment.
De fleste bivirkninger svinder ved passende behandling eller ved ophør med brug af Nivolumab BMS.
Most will resolve following appropriate treatment or on stopping Nivolumab BMS.
De fleste bivirkninger under behandling med Agenerase var af mild til moderat sværhedsgrad, startede tidligt i forløbet og var sjældent begrænsende for behandlingen.
Most undesirable effects associated with Agenerase therapy were mild to moderate in severity, early in onset, and rarely treatment-limiting.
De fleste bivirkninger var af grad 1 eller 2 i alvorlighed.
Most adverse reactions were Grade 1 or 2 in severity.
De fleste bivirkninger var af mild til moderat sværhedsgrad.
Most of the adverse reactions were mild to moderate in intensity.
De fleste bivirkninger var lette til moderate.
Most reactions were of mild-to-moderate grade.
De fleste bivirkninger var milde til moderate i intensitet.
Most side effects were mild to moderate in intensity.
De fleste bivirkninger ved Briviact var lette eller moderate og blev anset for at kunne behandles.
Most side effects of Briviact were of mild or moderate severity and were considered manageable.
De fleste bivirkninger vil ophøre efter en passende behandling, eller når patienten ikke længere får Yervoy.
Most will resolve following appropriate treatment or on stopping Yervoy.
De fleste bivirkninger, der blev observeret i de fem kliniske studier, var milde til moderate.
Most adverse drug reactions (ADRs) observed in the five clinical studies were mild to moderate in nature.
De fleste blødningshændelser hos patienter i behandling med Stivarga var lette til moderate i sværhedsgrad (grad 1 og 2: 16,9 %), hovedsageligt næseblod (7,6 %).
Most cases of bleeding events in patients treated with Stivarga were mild to moderate in severity (Grades 1 and 2: 16.9%), most notably epistaxis (7.6%).
De fleste børn med rotavirus-diaré bliver selv raske.
Most children with rotavirus diarrhoea recover on their own.
De fleste børn og unge med Crohns sygdom udviste også færre symptomer efter tilføjelse af Remicade til deres eksisterende behandling.
Most of the children and adolescents with Crohn’s disease also showed a reduction in symptoms after adding Remicade to their existing treatment.
De fleste data har indikeret, at et lille antal spædbørn opnåede antistofkoncentrationer ≥ 0,35 μg/ml (den af WHO anbefalede antistofkoncentration)1 mod serotyperne 6B og 23F efter en serie med to doser primærvaccination, når der sammenlignes direkte eller indirekte med serier bestående af tre doser primærvaccination.
Most of the data have indicated that smaller proportions of infants achieved antibody concentrations ≥0.35 μg/ml (the reference antibody concentration recommended by WHO)1 against serotypes 6B and 23F after two-dose primary series when directly or indirectly compared with three-dose primary series.
De fleste data har indikeret, at et lille antal spædbørn opnåede antistofkoncentrationer ≥ 0,35 μg/ml (den af WHO anbefalede antistofkoncentration)2 mod serotyperne 6B og 23F efter en serie med to doser primærvaccination, når der sammenlignes direkte eller indirekte med serier bestående af tre doser primærvaccination.
Most of the data have indicated that smaller proportions of infants achieved antibody concentrations ≥0.35 μg/ml (the reference antibody concentration recommended by WHO)2 against serotypes 6B and 23F after two-dose primary series when directly or indirectly compared with three-dose primary series.
De fleste epidemiologiske studier har dog hverken vist en øget risiko for fødselsdefekter hos børn født af kvinder, som tog ethinylestradiol p-piller før graviditeten eller en teratogen virkning ved uforvarende indtagelse af ethinylestradiol p-piller tidligt i graviditeten.
Most epidemiological studies have revealed neither an increased risk of birth defects in infants born to women who used ethinylestradiol-containing COCs prior to pregnancy, nor a teratogenic effect when ethinylestradiol- containing COCs were taken inadvertently during early pregnancy.
De fleste episoder var lette til moderate og forekom dosisafhængigt.
Most episodes were mild to moderate and occurred in a dose­dependent fashion.
De fleste forsøgsdeltagere havde LDH ≤ ULN (65 %), ECOG performance status 0 (72 %) og visceral sygdom (73 %) ved baseline.
Most subjects had LDH ≤ULN (65%), ECOG performance status of 0 (72%), and visceral disease (73%) at baseline.
De fleste forsøgsdeltagere havde LDH ≤ ULN (67 %), ECOG-performance status 0 (70 %) og visceral sygdom (78 %) ved baseline.
Most subjects had LDH ≤ULN (67%), ECOG performance status of 0 (70%), and visceral disease (78%) at baseline.
De fleste forsøgsdeltagere havde LDH ≤ULN (65 %), ECOG-performance-status 0 (72 %) og visceral sygdom (73 %) ved baseline.
Most subjects had LDH ≤ULN (65%), ECOG performance status of 0 (72%), and visceral disease (73%) at baseline.
De fleste forsøgspersoner (95,7 %) fik en enkelt præoperativ dosis til at opretholde hæmostase i løbet af operationen.
Most subjects (95.7%) received a single pre- operative dose to maintain haemostasis during surgery.